US 12,280,021 B2
Affinity medicant conjugate
Michael Kelner, La Jolla, CA (US)
Assigned to AF CHEMICALS, LLC, San Diego, CA (US)
Filed by Califia Pharma Inc., San Diego, CA (US)
Filed on Aug. 4, 2023, as Appl. No. 18/365,920.
Application 17/482,242 is a division of application No. 17/035,529, filed on Sep. 28, 2020, granted, now 11,135,182, issued on Oct. 5, 2021.
Application 18/365,920 is a continuation of application No. 17/576,767, filed on Jan. 14, 2022, abandoned.
Application 17/576,767 is a continuation of application No. 17/482,242, filed on Sep. 22, 2021, granted, now 11,241,398, issued on Dec. 6, 2021.
Application 17/035,529 is a continuation in part of application No. 15/986,727, filed on May 22, 2018, granted, now 10,806,708, issued on Oct. 22, 2020.
Application 15/986,727 is a continuation of application No. 15/201,301, filed on Jul. 1, 2016, granted, now 9,980,926, issued on Feb. 8, 2018.
Application 15/201,301 is a continuation of application No. 14/684,218, filed on Apr. 10, 2015, granted, now 9,381,178, issued on Jul. 5, 2016.
Claims priority of provisional application 61/978,195, filed on Apr. 10, 2014.
Prior Publication US 2023/0372267 A1, Nov. 23, 2023
Int. Cl. A61K 31/122 (2006.01); A61K 31/19 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 47/58 (2017.01); A61K 47/59 (2017.01); A61K 47/62 (2017.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01)
CPC A61K 31/122 (2013.01) [A61K 31/19 (2013.01); A61K 47/55 (2017.08); A61K 47/551 (2017.08); A61K 47/554 (2017.08); A61K 47/58 (2017.08); A61K 47/59 (2017.08); A61K 47/593 (2017.08); A61K 47/62 (2017.08); A61K 47/64 (2017.08); A61K 47/6415 (2017.08); A61K 47/642 (2017.08); A61K 47/65 (2017.08); A61K 47/68 (2017.08); A61K 47/6803 (2017.08); A61K 47/6889 (2017.08)] 20 Claims
 
1. A compound of the formula I

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, where X is selected from a first group consisting of —S— and —O—; R1 represents an antibody affinity moiety;
R3 is —H;
R2, R4 and R5 are —CH3; and
R6 is selected from a second group consisting of —CH3, —CH2—OH, —CH2—O(—(C═O)—CH3, —O—(C═O)—CH2—CH2—CH2—(C═O)—OH, —O(C═O)—C6H3(NO2)2, and —CH2—(C═O)—(CH3)2.